Basilea Pharmaceutica AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPMUF research report →
Companywww.basilea.com
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
- CEO
- David Veitch
- IPO
- 2015
- Employees
- 164
- HQ
- Allschwil, CH
Price Chart
Valuation
- Market Cap
- $805.59M
- P/E
- 20.37
- P/S
- 3.70
- P/B
- 5.14
- EV/EBITDA
- 18.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.32%
- Op Margin
- 21.94%
- Net Margin
- 17.90%
- ROE
- 27.95%
- ROIC
- 15.07%
Growth & Income
- Revenue
- $232.51M · 11.49%
- Net Income
- $40.22M · -48.17%
- EPS
- $3.29 · -48.75%
- Op Income
- $51.62M
- FCF YoY
- -18.01%
Performance & Tape
- 52W High
- $74.00
- 52W Low
- $47.50
- 50D MA
- $67.99
- 200D MA
- $62.85
- Beta
- 0.41
- Avg Volume
- 13
Get TickerSpark's AI analysis on BPMUF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BPMUF Coverage
We haven't published any research on BPMUF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BPMUF Report →